Stratos Wealth Partners LTD. grew its position in shares of Zoetis Inc (NYSE:ZTS) by 3.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,594 shares of the company’s stock after acquiring an additional 1,461 shares during the period. Stratos Wealth Partners LTD.’s holdings in Zoetis were worth $3,885,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Nordea Investment Management AB boosted its stake in Zoetis by 8.5% during the 3rd quarter. Nordea Investment Management AB now owns 98,738 shares of the company’s stock valued at $9,041,000 after purchasing an additional 7,737 shares during the last quarter. Vanguard Group Inc boosted its stake in shares of Zoetis by 0.8% in the 3rd quarter. Vanguard Group Inc now owns 35,947,496 shares of the company’s stock worth $3,291,353,000 after buying an additional 293,614 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Zoetis in the 4th quarter worth approximately $370,000. Steward Partners Investment Advisory LLC boosted its stake in shares of Zoetis by 53.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 8,075 shares of the company’s stock worth $690,000 after buying an additional 2,808 shares during the last quarter. Finally, BKD Wealth Advisors LLC boosted its stake in shares of Zoetis by 8.9% in the 4th quarter. BKD Wealth Advisors LLC now owns 2,741 shares of the company’s stock worth $234,000 after buying an additional 224 shares during the last quarter. 90.78% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE ZTS traded down $0.69 during midday trading on Friday, reaching $102.24. The company’s stock had a trading volume of 691,492 shares, compared to its average volume of 1,922,895. The company has a quick ratio of 2.79, a current ratio of 4.05 and a debt-to-equity ratio of 2.84. The company has a market capitalization of $48.75 billion, a PE ratio of 32.66, a PEG ratio of 2.55 and a beta of 0.91. Zoetis Inc has a 12-month low of $78.90 and a 12-month high of $103.97.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.09. The company had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. Zoetis’s revenue was up 6.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.75 EPS. As a group, research analysts expect that Zoetis Inc will post 3.48 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 19th will be issued a $0.164 dividend. The ex-dividend date is Thursday, July 18th. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.64%. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Zoetis from a “buy” rating to a “hold” rating in a research note on Monday, May 6th. Gabelli downgraded Zoetis from a “buy” rating to a “hold” rating and set a $108.00 target price on the stock. in a research note on Thursday, May 2nd. They noted that the move was a valuation call. Credit Suisse Group boosted their target price on Zoetis from $102.00 to $112.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 2nd. BMO Capital Markets boosted their target price on Zoetis from $101.00 to $105.00 and gave the stock a “market perform” rating in a research note on Thursday, May 9th. Finally, UBS Group assumed coverage on Zoetis in a research note on Wednesday, March 20th. They issued a “neutral” rating on the stock. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $103.15.

In related news, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $101.89, for a total value of $203,780.00. Following the sale, the insider now owns 30,727 shares of the company’s stock, valued at approximately $3,130,774.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $101.90, for a total transaction of $623,933.70. Following the completion of the sale, the executive vice president now directly owns 51,926 shares in the company, valued at approximately $5,291,259.40. The disclosure for this sale can be found here. Insiders sold a total of 439,784 shares of company stock worth $41,891,618 in the last ninety days. 0.29% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.mareainformativa.com/news/2019/05/17/zoetis-inc-zts-stake-boosted-by-stratos-wealth-partners-ltd.html.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: Benefits of owning preferred stock

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.